JAK2 V617F/C618R mutation in a patient with polycythemia vera:A case study and review of the literature

Cancer Genetics and Cytogenetics

Volumn 189, Issue 1, 2009, Pages 43-47

  Yoo, Jong Ha ^a,b   Park, Tae Sung ^b   Maeng, Ho Young ^a   Sun, Young Kyu ^a,b   Kim, Young Ah ^a,b   Kie, Jeong Hae ^a   Cho, Eun Hae ^c   Song, Jaewoo ^b   Lee, Kyung A ^b   Suh, Borum ^b   Choi, Jong Rak ^b  

^a National Health Insurance Corporation   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Green Cross Reference Laboratory   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; EXON; GENE MUTATION; HUMAN; HUMAN TISSUE; KARYOTYPE 46,XY; KOREA; MALE; POLYCYTHEMIA VERA; PRIORITY JOURNAL;

ADULT; BASE SEQUENCE; HUMANS; JANUS KINASE 2; MALE; MOLECULAR SEQUENCE DATA; POINT MUTATION; POLYCYTHEMIA VERA;

EID: 58249145185     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.09.010     Document Type: Article

References (30)

1. Shannon K., and Van Etten R.A. JAKing up hematopoietic proliferation. Cancer Cell 7 (2005) 291-293
2. James C., Ugo V., Le Couédic J.P., Staerk J., Delhommeau F., Lacout C., Garçon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., and Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
3. Lacout C., Pisani D.F., Tulliez M., Gachelin F.M., Vainchenker W., and Villeval J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108 (2006) 1652-1660
4. Tefferi A., and Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22 (2008) 14-22
5. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., and Green A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
6. Horn T., Kremer M., Dechow T., Pfeifer W.M., Geist B., Perker M., Duyster J., Quintanilla-Martinez L., and Fend F. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases. J Mol Diagn 8 (2006) 299-304
7. Levine R.L., Loriaux M., Huntly B.J., Loh M.L., Beran M., Stoffregen E., Berger R., Clark J.J., Willis S.G., Nguyen K.T., Flores N.J., Estey E., Gattermann N., Armstrong S., Look A.T., Griffin J.D., Bernard O.A., Heinrich M.C., Gilliland D.G., Druker B., and Deininger M.W. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106 (2005) 3377-3379
8. Kratz C.P., Böll S., Kontny U., Schrappe M., Niemeyer C.M., and Stanulla M. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 20 (2006) 381-383
9. Scott L.M., Scott M.A., Campbell P.J., and Green A.R. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 108 (2006) 2435-2437
10. Wang Y.L., Vandris K., Jones A., Cross N.C., Christos P., Adriano F., and Silver R.T. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia 22 (2008) 1289
11. Karow A., Waller C., Reimann C., Niemeyer C.M., and Kratz C.P. JAK2 mutations other than V617F: a novel mutation and mini review. Leuk Res 32 (2008) 365-366
12. Lee J.W., Kim Y.G., Soung Y.H., Han K.J., Kim S.Y., Rhim H.S., Min W.S., Nam S.W., Park W.S., Lee J.Y., Yoo N.J., and Lee S.H. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 25 (2006) 1434-1436
13. Zhang S.J., Li J.Y., Li W.D., Song J.H., Xu W., and Qiu H.X. The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient. Int J Lab Hematol 29 (2007) 71-72
14. Schnittger S., Bacher U., Kern W., Schröder M., Haferlach T., and Schoch C. Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 20 (2006) 2195-2197
15. Malinge S., Ben-Abdelali R., Settegrana C., Radford-Weiss I., Debre M., Beldjord K., Macintyre E.A., Villeval J.L., Vainchenker W., Berger R., Bernard O.A., Delabesse E., and Penard-Lacronique V. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 109 (2007) 2202-2204
16. Mercher T., Wernig G., Moore S.A., Levine R.L., Gu T.L., Fröhling S., Cullen D., Polakiewicz R.D., Bernard O.A., Boggon T.J., Lee B.H., and Gilliland D.G. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood 108 (2006) 2770-2779
17. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., Futreal P.A., Erber W.N., McMullin M.F., Harrison C.N., Warren A.J., Gilliland D.G., Lodish H.F., and Green A.R. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 (2007) 459-468
18. Williams D.M., Kim A.H., Rogers O., Spivak J.L., and Moliterno A.R. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol 35 (2007) 1641-1646
19. Grünebach F., Bross-Bach U., Kanz L., and Brossart P. Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera. Leukemia 20 (2006) 2210-2211
20. Kouroupi E., Zoi K., Parquet N., Zoi C., Kiladjian J.J., Grigoraki V., Vainchenker W., Lellouche F., Marzac C., Schlageter M.H., Dosquet C., Scott L.M., Fenaux P., Loukopoulos D., Chomienne C., and Cassinat B. Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients. Br J Haematol 42 (2008) 676-679
21. Pardanani A., Lasho T.L., Finke C., Hanson C.A., and Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 21 (2007) 1960-1963
22. Colaizzo D., Amitrano L., Tiscia G.L., Grandone E., Guardascione M.A., and Margaglione M. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 110 (2007) 2768
23. Pietra D., Li S., Brisci A., Passamonti F., Rumi E., Theocharides A., Ferrari M., Gisslinger H., Kralovics R., Cremonesi L., Skoda R., and Cazzola M. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 111 (2008) 1686-1689
24. Percy M.J., Scott L.M., Erber W.N., Harrison C.N., Reilly J.T., Jones F.G., Green A.R., and McMullin M.F. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica 92 (2007) 1607-1614
25. Martínez-Avilés L., Besses C., Alvarez-Larrán A., Cervantes F., Hernández-Boluda J.C., and Bellosillo B. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. Haematologica 92 (2007) 1717-1718
26. Butcher C.M., Hahn U., To L.B., Gecz J., Wilkins E.J., Scott H.S., Bardy P.G., and D'Andrea R.J. Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients. Leukemia 22 (2008) 870-873
27. Stój A., Rudzki Z., Stachura J., Sacha T., and Czekalska S. The JAK2 V617F mutation is frequently present in buccal swabs from patients suffering from Philadelphia-negative chronic myeloproliferative disorders, who carry the mutation detected in bone marrow or peripheral blood cells. J Clin Pathol 60 (2007) 1070-1071
28. Metaxas Y., Zeiser R., Schmitt-Graeff A., Waterhouse M., Faber P., Follo M., Bertz H., Finke J., and Spyridonidis A. Human hematopoietic cell transplantation results in generation of donor-derived epithelial cells. Leukemia 19 (2005) 1287-1289
29. Tran S.D., Pillemer S.R., Dutra A., Barrett A.J., Brownstein M.J., Key S., Pak E., Leakan R.A., Kingman A., Yamada K.M., Baum B.J., and Mezey E. Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study. Lancet 361 (2003) 1084-1088
30. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790